Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 96,363	$ 194,905
Short-term investments	1,228,499	1,140,445
Accounts receivable	36,802	43,213
Inventory	12,665	11,381
Advance payments to contract manufacturers	31,834	26,450
Other current assets	15,387	21,293
Total current assets	1,421,550	1,437,687
Long-term investments	279,119	582,889
Property, plant and equipment, net	64,999	48,851
Operating lease right-of-use assets	134,177	0
Goodwill	76,501	76,501
Other assets	1,010	4,244
Other assets	1,977,356	2,150,172
LIABILITIES AND STOCKHOLDERS’ EQUITY
Accounts payable	19,234	5,854
Accrued compensation	11,467	9,937
Accrued clinical trial expenses	32,626	14,700
Accrued contract manufacturing expenses	7,304	23,841
Other accrued expenses	11,414	9,087
Senior secured notes, net	248,693	0
Interest payable	4,198	4,198
Lease liability, current portion	12,516	0
Deferred revenue, current portion	5,517	13,892
Other current liabilities	924	493
Total current liabilities	353,893	82,002
Senior secured notes, net	0	246,950
Lease liability, less current portion	142,730	0
Liability related to the sale of future royalties, net	72,020	82,911
Deferred revenue, less current portion	2,554	10,744
Other long-term liabilities	768	9,990
Total liabilities	571,965	432,597
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.0001 par value; 10,000 shares authorized; no shares designated, issued or outstanding at December 31, 2019 or 2018	0	0
Common stock, $0.0001 par value; 300,000 shares authorized; 176,505 shares and 173,530 shares issued and outstanding at December 31, 2019 and 2018, respectively	17	17
Capital in excess of par value	3,271,097	3,147,925
Accumulated other comprehensive loss	(1,005)	(6,316)
Accumulated deficit	(1,864,718)	(1,424,051)
Total stockholders’ equity	1,405,391	1,717,575
Total liabilities and stockholders’ equity	$ 1,977,356	$ 2,150,172